MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
J-104871
CAS :<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Formule :C38H32N2O12Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :708.67PS-166276
CAS :<p>PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.</p>Formule :C20H30N8OCouleur et forme :SolidMasse moléculaire :398.51Luvometinib
CAS :<p>Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.</p>Formule :C26H22F2IN5O4SCouleur et forme :SolidMasse moléculaire :665.45KRAS inhibitor-31
CAS :<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Formule :C33H30F3N5O4Couleur et forme :SolidMasse moléculaire :617.62KRAS G12D inhibitor 16
CAS :<p>KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.</p>Formule :C32H39IN6O3Couleur et forme :SolidMasse moléculaire :682.59KRAS inhibitor-32
CAS :<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Formule :C29H35FN10OS2Couleur et forme :SolidMasse moléculaire :622.78KRas G12C inhibitor 2
CAS :<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Formule :C32H37N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :567.68KRAS inhibitor-37
CAS :<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Formule :C32H33ClFN7O3Couleur et forme :SolidMasse moléculaire :618.10JNK-1-IN-4
CAS :<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>Formule :C22H25BrN6O3Couleur et forme :SolidMasse moléculaire :501.38KRAS G12C inhibitor 20
CAS :<p>KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.</p>Formule :C33H37ClFN7O3Couleur et forme :SolidMasse moléculaire :634.14FMK-MEA
CAS :<p>FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.</p>Formule :C21H26FN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :399.46KRAS G12D inhibitor 26
CAS :<p>KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.</p>Formule :C35H44ClFN8O2Degré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :663.23SR-302
CAS :<p>SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.</p>Formule :C32H42N6O5SCouleur et forme :SolidMasse moléculaire :622.778(R)-STU104-d6
CAS :<p>(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.</p>Formule :C18H182D6O4Couleur et forme :SolidMasse moléculaire :304.37pan-KRAS degrader 1
CAS :<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Formule :C22H26N8OSCouleur et forme :SolidMasse moléculaire :450.56KRAS G12C inhibitor 56
CAS :<p>KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.</p>Formule :C32H39N7O4SCouleur et forme :SolidMasse moléculaire :617.76p38α MAPK/CK1δ inhibitor-1
CAS :<p>p38αMAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.</p>Formule :C24H17FN6O2Couleur et forme :SolidMasse moléculaire :440.429MRTX849 acid
CAS :<p>MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.</p>Formule :C34H37ClFN7O4Couleur et forme :SolidMasse moléculaire :662.16MRTX-EX185
<p>MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.</p>Formule :C33H33FN6O2Couleur et forme :SolidMasse moléculaire :564.65KRASG12C IN-15
CAS :<p>KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.</p>Formule :C31H32FN3O2Couleur et forme :SolidMasse moléculaire :497.603
